Rose McNulty

Researchers found a causal association between insomnia and atopic dermatitis and identified several genetic variations contributing to the association.

Fecal immunochemical testing (FIT) was more accurate than blood-based testing for detecting advanced precancerous colorectal lesions, a comparative study found.

Manmeet Ahluwalia, MD, MBA, FASCO, chief of medical oncology, chief scientific officer, and deputy director of the Miami Cancer Institute of Baptist Health South Florida, discusses a groundbreaking clinical trial for non-small cell lung cancer (NSCLC) brain metastases.

Iron deficiency anemia increased the risk of death from any cause, while non-iron deficiency anemia was linked with an increased risk of cardiovascular disease (CVD)-related death in rheumatoid arthritis.

Advancements in gene therapy for Duchenne muscular dystrophy (DMD) have improved the outlook for some patients, but further innovations in safety, efficacy, and treatment strategies are needed.

A new analysis suggests artificial intelligence algorithms are able to accurately assess lesion severity in patients with atopic dermatitis.

Genetic testing for hereditary cancer unexpectedly uncovers a case of myelodysplastic syndrome (MDS), highlighting the need for careful interpretation of results and multidisciplinary collaboration.

People with chronic lymphocytic leukemia (CLL) saw a 55% year-to-year increase in all-cause mortality in the early days of the pandemic, a Swedish study found.

A new device was able to distinguish between mild and very severe chronic obstructive pulmonary disease (COPD).

Patients with chronic conditions are less likely to be diagnosed via screening and face higher mortality when cancer is detected in emergency settings, according to one study.

The findings suggest assessment of CD20 may be an important factor in determining treatment options in B-cell lymphomas.

The findings highlight the limits of risk stratification algorithms based on data from older patients.

Patients with vitiligo experience impacts on quality of life, emerging therapies offer promising prospects for more targeted and effective treatments, though further research is needed to confirm their safety, efficacy, and optimal use.

Patients reported that side effects often impacted their quality of life (QOL). However, most patients said their treatment helped slow disease progression and gave them hope.

Recent research reveals COVID-19 significantly increases long-term kidney dysfunction risk compared with influenza, especially in older adults and men.

The rate of rheumatoid arthritis (RA) has increased over the last 32 years, with certain groups of interest facing higher burden, finds a new analysis.

New findings suggest that reducing the variant allele frequency of JAK2V617F should be a goal of treatment for polycythemia vera.

Delandistrogene moxeparvovec, a gene therapy for Duchenne muscular dystrophy (DMD), showed high dystrophin expression and a favorable safety profile in young patients.

Elevated LDH and higher international prognostic index were also predictors of poor outcomes on bispecific antibodies, investigators found.

New research reveals light sensitivity significantly impacts quality of life in myasthenia gravis patients, highlighting the need for targeted treatment strategies.

The findings, which add to the limited data on the burden of atopic dermatitis on adolescent and pediatric patients, showed differences in what was most bothersome to the younger group of patients.

Patients with extensive-stage small cell lung cancer (SCLC) experienced clinically meaningful benefits with lurbinectedin plus atezolizumab vs atezolizumab in the phase 3 IMforte trial, according to findings being presented at the ASCO Annual Meeting.

Luspatercept showed real-world efficacy among patients with lower-risk myelodysplastic syndrome (MDS), confirming results seen in clinical trials.

Even a 2% decline in lung function predicted poor outcomes for patients with idiopathic pulmonary fibrosis (IPF) in a new study.

The ALPHA3 trial is exploring cemacabtagene ansegedleucel's (cema-cel) potential to enhance outcomes in patients who have relapsed/refractory large B-cell lymphoma, particularly those positive for minimal residual disease.

Margrit Wiesendanger, MD, PhD, explores lupus symptoms, diagnosis challenges, and the importance of early detection to prevent inflammation-related damage.

The tool could make it easier for clinicians to rule out melanoma without the need for excision.

The real-world data showed lower rates of atrial fibrillation and hypertension associated with the second-generation Bruton tyrosine kinase inhibitor among patients with chronic lymphocytic leukemia (CLL).